Beckham's Vitamin Drink Lands $1B From VC Fund That Doesn't Do Equity

David Beckham's longevity vitamin drink company IM8 has somehow convinced General Catalyst to part with $1 billion—a feat made only slightly more bizarre by the fact that General Catalyst's Customer Value Fund doesn't actually make equity investments. Let that sink in: a venture capital firm famous for disciplined checks into infrastructure software and developer tools has decided that the path forward involves $1 billion in non-equity capital to a celebrity-backed beverage startup. The fund's structure is so unusual that it required its own acronym (CVF) just to exist, which is always a red flag in an industry already drowning in branded obscurity.

IM8 is, by all available accounts, a longevity vitamin drink—the exact category that has somehow convinced wealthy people that drinking something with expensive ingredients will extend their lifespan by virtue of famous people being associated with it. The company's primary asset appears to be David Beckham's name, his still-considerable social media following, and the general belief that athletic achievement in one domain translates to expertise in cellular biology. There is no publicly available information suggesting IM8 has achieved the kind of revenue, unit economics, or scientific validation that would justify a $1 billion valuation from a serious institutional investor—which is perhaps why General Catalyst had to invent a new fund structure that operates outside normal equity conventions.

General Catalyst, to be fair, has built a legitimate reputation over two decades of steady, profitable investing in companies that actually needed the capital and had clear paths to revenue. But $1 billion for a vitamin drink suggests either unprecedented confidence in the longevity category or an unprecedented willingness to redefine what "venture capital" means when the alternative is watching this deal go to a less intellectually flexible competitor. The Customer Value Fund appears to be the financial equivalent of a legal opinion: a way to make something structurally irregular sound methodologically sound.

The press materials surely read something like this: "General Catalyst's CVF provides non-dilutive capital to align stakeholder incentives across customer acquisition and retention lifecycles." Translation: we found a way to give Beckham a billion dollars without admitting we're betting on celebrity and Instagram followers. The beverage space is littered with similarly well-capitalized ventures that discovered too late that distribution is harder than brand partnerships and that consumers don't care about longevity claims unless they're backed by something more rigorous than a retired soccer player's aesthetics.

The real risk here isn't IM8's product or market—it's that General Catalyst has now created a precedent. If a $1 billion non-equity instrument makes sense for a celebrity vitamin drink, what exactly is the limiting principle? Other mega-funds will follow, venture capital will become increasingly divorced from equity ownership and actual ownership stakes, and the entire mechanism will become another financial product designed to move capital in directions that make accountants happy and fundamentals irrelevant.

What this deal really demonstrates is that institutional venture capital has so much money to deploy that it will eventually fund anything that has a famous person attached and a plausible pitch deck. The Customer Value Fund isn't a new innovation—it's a symptom of capital abundance so extreme that even the gatekeepers have stopped pretending to have actual gates.

At least when beverage startups fail, the evidence will be refreshing.